Trends in Cardiovascular Medicine
Volume 16, Issue 2 , Pages 50-55 , February 2006

Caveolin-1: Dual Role for Proliferation of Vascular Smooth Muscle Cells

  • Daniel G. Sedding
    • ,
  • Ruediger C. Braun-Dullaeus

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Ruediger C. Braun-Dullaeus, MD, Department of Internal Medicine/Cardiology, Dresden University of Technology, Fetscherstrasse 76, D-01307 Dresden, Germany. Tel.: (+49) 351-450-1701; fax: (+49) 351-450-1702.

References 

  1. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: The role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev. 1998;50:197–263
  2. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression. New therapeutic target for vascular proliferative disease. Circulation. 1998;98:82–89
  3. Capozza F, Williams TM, Schubert W, et al. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol. 2003;162:2029–2039
  4. Chapman GB, Durante W, Hellums JD, Schafer AI. Physiological cyclic stretch causes cell cycle arrest in cultured vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2000;278:H748–H754
  5. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293:2449–2452
  6. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med. 2002;8:1249–1256
  7. Engelman JA, Wykoff CC, Yasuhara S, et al. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem. 1997;272:16374–16381
  8. Frank PG, Lee H, Park DS, et al. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:98–105
  9. Galbiati F, Volonte D, Engelman JA, et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 1998;17:6633–6648
  10. Gratton JP, Bernatchez P, Sessa WC. Caveolae and caveolins in the cardiovascular system. Circ Res. 2004;94:1408–1417
  11. Gustavsson J, Parpal S, Karlsson M, et al. Localization of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB J. 1999;13:1961–1971
  12. Hassan GS, Jasmin JF, Schubert W, et al. Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry. 2004;43:8312–8321
  13. Kawabe J, Okumura S, Lee MC, et al. Translocation of caveolin regulates stretch-induced ERK activity in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2004;286:H1845–H1852
  14. Khan BV, Harrison DG, Olbrych MT, et al. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci U S A. 1996;93:9114–9119
  15. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci U S A. 1995;92:1381–1385
  16. Krajewska WM, Maslowska I. Caveolins: Structure and function in signal transduction. Cell Mol Biol Lett. 2004;9:195–220
  17. Lee SW, Reimer CL, Oh P, et al. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 1998;16:1391–1397
  18. Li C, Xu Q. Mechanical stress-initiated signal transductions in vascular smooth muscle cells. Cell Signal. 2000;12:435–445
  19. Li XA, Everson WV, Smart EJ. Caveolae, lipid rafts, and vascular disease. Trends Cardiovasc Med. 2005;15:92–96
  20. Liu P, Ying Y, Ko YG, Anderson RG. Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. J Biol Chem. 1996;271:10299–10303
  21. Molloy CJ, Taylor DS, Pawlowski JE. Novel cardiovascular actions of the activins. J Endocrinol. 1999;161:179–185
  22. Peterson TE, Kleppe LS, Caplice NM, et al. The regulation of caveolin expression and localization by serum and heparin in vascular smooth muscle cells. Biochem Biophys Res Commun. 1999;265:722–727
  23. Peterson TE, Guicciardi ME, Gulati R, et al. Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol. 2003;23:1521–1527
  24. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001;276:38121–38138
  25. Rizzo V, McIntosh DP, Oh P, Schnitzer JE. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J Biol Chem. 1998;273:34724–34729
  26. Rizzo V, Morton C, DePaola N, et al. Recruitment of endothelial caveolae into mechanotransduction pathways by flow conditioning in vitro. Am J Physiol Heart Circ Physiol. 2003;285:H1720–H1729
  27. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature. 1993;362:801–809
  28. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973;180:1332–1339
  29. Schnitzer JE, Oh P, Jacobson BS, Dvorak AM. Caveolae from luminal plasmalemma of rat lung endothelium: Microdomains enriched in caveolin, Ca(2+)–ATPase, and inositol trisphosphate receptor. Proc Natl Acad Sci U S A. 1995;92:1759–1763
  30. Schwartz SM, DeBlois D, O'Brien ERM. The intima. Soil for atherosclerosis and restenosis. Circ Res. 1995;77:445–465
  31. Schwartz SM, Virmani R, Rosenfeld ME. The good smooth muscle cells in atherosclerosis. Curr Atheroscler Rep. 2000;2:422–429
  32. Schwencke C, Schmeisser A, Walter C, et al. Decreased caveolin-1 in atheroma: Loss of antiproliferative control of vascular smooth muscle cells in atherosclerosis. Cardiovasc Res. 2005;68:128–135
  33. Sedding DG, Seay U, Fink L, et al. Mechanosensitive p27Kip1 regulation and cell cycle entry in vascular smooth muscle cells. Circulation. 2003;108:616–622
  34. Sedding DG, Hermsen J, Seay U, et al. Caveolin-1 facilitates mechanosensitive protein kinase B (Akt) signaling in vitro and in vivo. Circ Res. 2005;96:635–642
  35. Sonveaux P, Martinive P, DeWever J, et al. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res. 2004;95:154–161
  36. Virchow R. Der atheromathöse Prozess der Arterien. Wien Med Wochenschr. 1856;6:825–832
  37. Von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995;92:1137–1141
  38. Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell. 1998;94:625–634
  39. Williams TM, Hassan GS, Li J, et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: Genetic ablation of cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem. 2005;280:25134–25145
  40. Xu Q, Liu Y, Gorospe M, et al. Acute hypertension activates mitogen-activated protein kinases in arterial wall. J Clin Invest. 1996;97:508–514
  41. Yamamoto M, Toya Y, Schwencke C, et al. Caveolin is an activator of insulin receptor signaling. J Biol Chem. 1998;273:26962–26968
  42. Yang G, Truong LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998;4:1873–1880

PII: S1050-1738(05)00221-5

doi: 10.1016/j.tcm.2005.11.007

Trends in Cardiovascular Medicine
Volume 16, Issue 2 , Pages 50-55 , February 2006

Article Tools

* Image Usage & Resolution